அண்டர்ரைட்டர் விருப்பம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from அண்டர்ரைட்டர் விருப்பம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In அண்டர்ரைட்டர் விருப்பம் Today - Breaking & Trending Today

Auxly Announces $15.0 Million Bought-Deal Public Offering

Share:
TORONTO, June 09, 2021 (GLOBE NEWSWIRE) Auxly Cannabis Group Inc. (
Auxly or the
Company ) (TSX:XLY) (OTCQX:CBWTF) is pleased to announce that it has entered into an agreement pursuant to which ATB Capital Markets Inc. (
ATB ), as sole bookrunner, and Cantor Fitzgerald Canada Corporation, acting as co-lead underwriters of the Offering, together with a syndicate of underwriters (collectively, the
Underwriters ), will purchase 47,620,000 Units of the Company (the
Units ), on a bought-deal basis at a price per Unit of $0.315 (the
Issue Price ) for gross proceeds of $15,000,300 (the
Offering ). A.G.P./Alliance Global Partners is acting as the sole U.S. sub-agent and financial advisor to the Company in connection with the Offering in the United States. ....

United States , Hugo Alves , National Instrument , Investor Relations Team , Units Of The Company , A Gp Alliance Global Partners , Cantor Fitzgerald Canada Corporation , Capital Markets Inc , Shelf Prospectus , Auxly Cannabis Group Inc , Cannabis Group , Alliance Global Partners , Common Share , Each Warrant , Underwriter Option , Short Form Prospectus Distributions , Prospectus Supplement , Base Shelf Prospectus , Base Shelf , United States Securities Act , Auxly Cannabis Group , Regarding Forward Looking Information , ஒன்றுபட்டது மாநிலங்களில் , ஹ்யூகோ ஆல்வ்ஸ் , தேசிய கருவி , முதலீட்டாளர் உறவுகள் அணி ,

Investegate |Centessa Pharmaceuticals plc Announcements | Centessa Pharmaceuticals plc: Centessa Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional ADSs

Investegate announcements from Centessa Pharmaceuticals plc, Centessa Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs ....

New York , United States , United Kingdom , City Of , Mary Clark Shabnam Bashir , Dan Budwick , Jennifer Porcelli , Morgan Stanley , Exchange Commission On , Prospectus Department , Strategic Communications , Equity Syndicate Prospectus Department , Goldman Sachs Co , Evercore Group , Centessa Pharmaceuticals , Morgan Stanley Co , Centessa Announces Closing , Initial Public Offering , Full Exercise , Underwriter Option , Purchase Additional , Depositary Shares , Goldman Sachs , Exchange Commission , Equity Capital Markets , Shabnam Bashir ,

Eloxx Pharmaceuticals : Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares (Form 8-K)

Message :
Required fields
Eloxx Pharmaceuticals, Inc. Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters Option to Purchase Additional Shares
WALTHAM, Mass., May 18, 2021 (GLOBE NEWSWIRE) - Eloxx Pharmaceuticals, Inc. (the Company ) (Nasdaq: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced the closing of an underwritten public offering of 38,333,334 shares of common stock at a public offering price of $1.35 per share. The closing included the full exercise of the underwriters option to purchase an additional 5,000,000 shares of common stock at the public offering price, less underwriting discounts and commissions. Aggregate gross proceeds from the offering were approximately $51.75 million, before deducting underwriting discounts and commissions and offering expenses. ....

United States , John Woolford , Laureen Cassidy , Exchange Commission , Prospectus Department , Company Nasdaq , B Riley Securities Inc , Eloxx Pharmaceuticals Inc , Eloxx Pharmaceuticals , Announces Closing , Public Offering , Common Stock Including Full Exercise , Underwriter Option , Purchase Additional , Annual Report , Quarterly Report , ஒன்றுபட்டது மாநிலங்களில் , ஜான் கம்பளி , லாரீன் காசிடி , பரிமாற்றம் தரகு , ப்ரோஸ்பெக்டஸ் துறை , நிறுவனம் நாஸ்டாக் , பொது பிரசாதம் , பொதுவானது ஸ்டாக் உட்பட முழு உடற்பயிற்சி , அண்டர்ரைட்டர் விருப்பம் , ஆண்டு அறிக்கை ,

Vivos Therapeutics : Announces Closing of Follow-On Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares (Form 8-K)

Message :
Required fields
Vivos Therapeutics Announces Closing of Follow-On Offering and Exercise in Full of the Underwriters Option to Purchase Additional Shares
HIGHLANDS RANCH, Colo., May 11, 2021 - Vivos Therapeutics, Inc. (Nasdaq: VVOS) ( Vivos ), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today announced the closing of its underwritten follow-on public offering of 4,600,000 shares of its common stock. The offering consisted of 4,000,000 shares of its common stock, as well as an additional 600,000 shares pursuant to the exercise in full of the underwriters option to purchase additional shares of common stock, at a public offering price of $6.00 per share. ....

New York , United States , Caitlin Kasunich Jenny Robles , Edward Loew , Exchange Commission On , Craig Hallum Capital Group , Exchange Commission , Vivos Therapeutics Inc , Prospectus Department , Strategic Communications , National Securities Corporation , Vivos Therapeutics Announces Closing , Follow On Offering , Underwriter Option , Purchase Additional , Capital Partners , Securities Corporation , Roth Capital Partners , Clemente Drive , Newport Beach , Ninth Street , Equity Capital Markets , Vivos Therapeutics , Vivos System , Apnea Hypopnea Index , Vivos Integrated Practice ,

Aeterna Zentaris Reports First Quarter 2021 Financial

expected
beyond 2023
CHARLESTON, S.C., May 05, 2021 (GLOBE NEWSWIRE) Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today reported its financial and operating results for the first quarter ended March 31, 2021. The Company also provided an update on its preclinical and clinical development programs.
“Over the course of the first quarter, we continued to execute on our key strategic priorities by significantly strengthening our balance sheet and expanding our development pipeline. This solid execution provides us with optionality to advance and accelerate our pipeline programs,” commented Dr. Klaus Paulini, Chief Executive Officer of Aeterna. ....

United Kingdom , Klaus Paulini , Novo Nordisk Biopharm Limited , Aeterna Zentaris , University Of Queensland , Queensland University , University Of Sheffield , Vaccine Development Pipeline , Aeterna Zentaris Inc , Diagnostics Development Pipeline , Research Agreement , Pivotal Phase , Chief Executive Officer , Clinical Programs Update , Vaccine Development , Clearance Parathyroid Hormone , Fusion Polypeptides , Underwriter Option , First Quarter , ஒன்றுபட்டது கிஂக்டம் , பல்கலைக்கழகம் ஆஃப் குயின்ஸ்லாந்து , குயின்ஸ்லாந்து பல்கலைக்கழகம் , பல்கலைக்கழகம் ஆஃப் ஷெஃபீல்ட் , முக்கிய கட்டம் , தலைமை நிர்வாகி அதிகாரி , தடுப்பூசி வளர்ச்சி ,